Loading stock data…
ImmuCell Corporation (ICCC)
$9.91+0.12 (+1.23%)
Market ClosedLast close Jun 29
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImmuCell Corporation in the Healthcare sector is trading at $9.91 with a market capitalization of $86M. The stock is currently near its 52-week high of $10.75, remaining 42.6% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.36M↑ | $7.63M↑ | $5.51M↓ | $6.44M↓ | $8.07M |
| Gross Profit | $4.66M↑ | $2.91M↑ | $2.36M↓ | $2.82M↓ | $3.35M |
| Operating Income | $1.97M↑ | -$57,956↓ | $20,075↓ | $569,562↓ | $1.12M |
| Net Income | $1.94M↑ | -$2.85M↓ | -$139,748↓ | $501,880↓ | $1.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Masti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$85.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.87%
Volume
Today's trading volume
21,637
Recent News
The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell
Micron surged after strong Q3 results, robust AI-driven memory demand and a bullish Q4 outlook. See which ETFs have notable exposure.
Top Stock Reports for JPMorgan, Novartis & Qualcomm
JPMorgan, Novartis and Qualcomm headline today's top stock reports, highlighting growth drivers, competitive pressures and key catalysts ahead.
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
ImmuCell's premium valuation is backed by rising output, First Defense share gains and a sizable untapped calf-health market opportunity.
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
ICCC posts record Q1 sales and 34% earnings growth as demand for its First Defense calf-health products boosts margins and market share.
ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth
ImmuCell Corp (ICCC) achieves its first-ever $10 million revenue quarter, driven by strong domestic sales and strategic product expansions.